Hematopoietic cells from the malignant clone in chronic my-elogenous leukemia (CML) maintain and expand a prolifera-tive advantage over normal hematopoietic cells within the bone marrow. This advantage is often ameliorated or reversed in vivo by IFNa. Based upon earlier studies suggesting decreased adhe-siveness ofCML progenitor cells, we asked whetherCML pro-genitor cells are deficient in their expression of the cytoadhe-sion molecule lymphocyte function antigen-3 (LFA-3, CD58) which is normally expressed on hematopoietic progenitors. Progenitor cells from untreated CML patients showed greatly reduced or absent LFA-3 expression, whereas progenitors from patients treated with IFNa in vivo or in vitro expressed surface LFA-3 at more normal l...
As an alternative treatment with allogeneic bone marrow transplantation, a possibility of autologous...
We investigated the effects of brief (2 h) and continuous exposure to recombinant interferon-alpha2a...
textabstractIFN-alpha has been shown to prolong survival in chronic myeloid leukemia pati...
Chronic myelogenous leukemia (CML) progenitors show decreased adhesion to stroma and fibronectin (FN...
International audienceInterferon alpha (IFN-alpha) is used to treat chronic myelogenous leukaemia (C...
INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patien...
INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patien...
Hematopoiesis takes place in close contact with the marrow microenvironment. Normal progenitors adhe...
Chronic myelogenous leukemia (CML) is a malignant disease of the hematopoietic stem cell characteriz...
Although interferon-alpha (IFN-alpha) induces hematologic remissions in 70% to 80% of patients with ...
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia arising from the oncogenic b...
Chronic myelogenous leukemia (CML) is characterized by the continuous proliferation and abnormal cir...
INTRODUCTION: Interferon-alpha (IFN) plays a role in the management of different neoplasias, particu...
Treatment with interferon-alpha is effective for chronic myelogenous leukemia in the chronic phase (...
Interferon-alpha (IFN-alpha) is an established treatment for chronic myelogenous leukemia (CML) in c...
As an alternative treatment with allogeneic bone marrow transplantation, a possibility of autologous...
We investigated the effects of brief (2 h) and continuous exposure to recombinant interferon-alpha2a...
textabstractIFN-alpha has been shown to prolong survival in chronic myeloid leukemia pati...
Chronic myelogenous leukemia (CML) progenitors show decreased adhesion to stroma and fibronectin (FN...
International audienceInterferon alpha (IFN-alpha) is used to treat chronic myelogenous leukaemia (C...
INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patien...
INTRODUCTION: Normal immature hematopoietic progenitors are relatively well preserved in most patien...
Hematopoiesis takes place in close contact with the marrow microenvironment. Normal progenitors adhe...
Chronic myelogenous leukemia (CML) is a malignant disease of the hematopoietic stem cell characteriz...
Although interferon-alpha (IFN-alpha) induces hematologic remissions in 70% to 80% of patients with ...
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasia arising from the oncogenic b...
Chronic myelogenous leukemia (CML) is characterized by the continuous proliferation and abnormal cir...
INTRODUCTION: Interferon-alpha (IFN) plays a role in the management of different neoplasias, particu...
Treatment with interferon-alpha is effective for chronic myelogenous leukemia in the chronic phase (...
Interferon-alpha (IFN-alpha) is an established treatment for chronic myelogenous leukemia (CML) in c...
As an alternative treatment with allogeneic bone marrow transplantation, a possibility of autologous...
We investigated the effects of brief (2 h) and continuous exposure to recombinant interferon-alpha2a...
textabstractIFN-alpha has been shown to prolong survival in chronic myeloid leukemia pati...